Opinion of Czech expert societies to consensus of European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine to determination of blood lipids and to interpretation of its values
Authors:
V. Soška 1,2; J. Franeková 3; B. Friedecký 4,5; A. Jabor 3; P. Kraml 6; H. Rosolová 7; M. Vráblík 8*
Authors‘ workplace:
Katedra laboratorních metod, Lékařská fakulta Masarykovy univerzity, Brno
; International Clinical Research Center, Fakultní nemocnice U sv. Anny v Brně
; Oddělení klinické biochemie
1; II. interní klinika
2; Pracoviště laboratorních metod IKEM Praha a 3. Lékařská fakulta Univerzity Karlovy v Praze
3; SEKK spol. s r. o., Pardubice
4; Ústav klinické biochemie a diagnostiky, Lékařská fakulta Univerzity Karlovy v Hradci Králové, Fakultní
nemocnice Hradec Králové
5; Centrum pro výzkum diabetu, metabolizmu a výživy, 2. interní klinika 3. Lékařské fakulty Univerzity Karlovy
a Fakultní nemocnice Královské Vinohrady, Praha
6; 2. Interní klinika Fakultní nemocnice v Plzni, Univerzita Karlova, Lékařská fakulta v Plzni
7; 3. interní klinika 1. lékařské fakulty a Všeobecné fakultní nemocnice v Praze
8
Published in:
Klin. Biochem. Metab., 25, 2017, No. 1, p. 36-42
Category:
Recommendation
Tato doporučení jsou dílem společné pracovní skupiny, kterou vytvořily Česká
společnost pro aterosklerózu a Česká společnost klinické biochemie
*Pozn: za společnou pracovní skupinu
Overview
The aim of this opinion is to summarize and to comment the consensus of the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine, which covers two main areas: 1) whether it is necessary/required to be fasting or non-fasting before blood sampling for lipids measurement, and what are the changes in the concentration of blood lipids during the day; 2) What decision limits (cut points value) of lipids and lipoproteins should be reported from laboratories and what is the recommended procedure for people with extreme / critical blood lipid values. Following parameters are discused: total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, lipoprotein(a). This opinion should be the object of interest both for professionals in clinical laboratories and for physicians in hospitals and out-patients departments.
Keywords:
blood collection, cut points limits, cholesterol, triglycerides, lipoprotein(a), apolipoproteins.
Sources
1. Nordestgaard, B. G., Langsted, A., Mora, S. et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications inclu-ding flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart. J., 2016, 37, p. 1944-1958.
2. Friedewald, W. T., Levy, R. I., Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18, p. 499-502.
3. Mora, S., Rifai, N., Buring, J. E. et al. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin. Chem., 2009, 55, p. 888-894.
4. Tanno, K., Okamura, T., Ohsawa, M. et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin. Chim. Acta, 2010, 411, p. 1774-1780.
5. Piepoli, M. F., Hoes, A. W., Agewall, S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016.
6. Soska, V., Vaverkova, H., Vrablik, M. et al. [Opi-nion of the Czech Atherosclerosis Society’s committee (CSAT) on the ESC/EAS guidelines related to the dia-gnostics and treatment of dyslipidemias issued in 2011]. Vnitr. Lek., 2013, 59, p. 120-126.
7. Catapano, A. L., Graham, I., De Backer, G. et al. ESC/EAS 2016 guidelines for the management of dyslipidemias. European Heart Journal 2016; doi:10.1093/eurheartj/ehw272.
8. Vaverková, H., Soška, V., Rosolová, H. et al. [Czech Atherosclerosis Society Guidelines for the diagnosis and treatment of dyslipidemias in adults]. Vnitr. Lek., 2007, 53, p. 181-187.
9. Guadagno, P. A., Summers Bellin, E. G., Harris, W. S. et al. Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin. Chim. Acta, 2015, 439, p. 219-224.
10. McConnell, J. P., Guadagno, P. A., Dayspring, T. D. et al. Lipoprotein(a) mass: a massively misunderstood metric. J Clin. Lipidol., 2014, 8, p. 550-553.
11. Raal, F. J., Giugliano, R. P., Sabatine, M. S. et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am. Coll. Cardiol., 2014, 63, p. 1278-1288.
12. Franeková, J., Jabor, A., Soška, V. Vliv standardní zátěže tukem na koncentrace triacylglycerolů a HDL-cholesterolu. FONS 2016, 26, p. 22-24.
13. Langsted, A., Freiberg, J. J., Nordestgaard, B.G. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation, 2008, 118, p. 2047-2056.
14. Emerging Risk Factors C, Di Angelantonio, E., Sarwar, N. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302, p. 1993-2000.
15. Driver, S. L., Martin, S. S., Gluckman, T. J. et al. Fasting or Nonfasting Lipid Measurements: It Depends on the Question. J Am. Coll. Cardiol., 2016, 67, p. 1227-1234.
16. Soška, V., Zima, T., Friedecký, B. et al. Společné doporučení České společnosti klinické biochemie ČLS JEP a České společnosti pro aterosklerózu ČLS JEP ke sjednocení hodnotících mezí krevních lipidů a lipoproteinů pro dospělou populaci. Klin. Biochem. Metab., 2010, 18, p. 45-46.
Labels
Clinical biochemistry Nuclear medicine Nutritive therapistArticle was published in
Clinical Biochemistry and Metabolism
2017 Issue 1
Most read in this issue
- Mild Hyperhomocysteinemias From Deficiency of MTHFR (C677T and C1298A) in Adults and Adolescents Attending Metabolic Unit: Is There Any Necessity for Their Differentiation and Treatment?
- Intoxication with ethylene glycol and falsely increased plasma lactate concentration
- Nutrition and metabolism of the bone
- Relationship between cold water swimming and increased cardiac markers: A pilot study